{"nctId":"NCT01806597","briefTitle":"Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis","startDateStruct":{"date":"2013-06-19","type":"ACTUAL"},"conditions":["Moderate to Severe Palmoplantar Psoriasis"],"count":205,"armGroups":[{"label":"secukinumab 150mg","type":"EXPERIMENTAL","interventionNames":["Biological: secukinumab 150 mg"]},{"label":"secukinumab 300 mg","type":"EXPERIMENTAL","interventionNames":["Biological: secukinumab 300 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"secukinumab 150 mg","otherNames":["AIN457 150 mg"]},{"name":"secukinumab 300 mg","otherNames":["AIN457 300 mg"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with chronic, moderate to severe plaque type psoriasis for at least 6 months prior to randomization and significant involvement of the palms and soles at baseline, defined as palmoplantar Investigator's Global Assessment (ppIGA) score of ≥ 3 on a 5-point scale, as well as at least one skin plaque at baseline which is not in the palmoplantar area\n* Candidates for systemic therapy, i.e. psoriasis inadequately controlled by topical treatment (including super potent topical corticosteroids) and/or phototherapy and/or previous systemic therapy\n\nExclusion Criteria:\n\n* Forms of psoriasis other than chronic plaque type psoriasis (e.g., pustular psoriasis, palmoplantar pustulosis, acrodermatitis of Hallopeau, erythrodermic and guttate psoriasis)\n* Drug-induced psoriasis (e.g. new onset or current exacerbation from β-blockers, calcium channel inhibitors or lithium)\n* Ongoing use of prohibited treatments (e.g. topical or systemic corticosteroids (CS), UV therapy). Washout periods do apply.\n* Prior exposure to secukinumab (AIN457) or any other biological drug directly targeting IL-17 or the IL-17 receptor\n* Use of any investigational drugs within 4 weeks prior to study treatment initiation or within a period of 5 half-lives of the investigational treatment, whichever is longer\n* Active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of secukinumab therapy\n* History of hypersensitivity to constituents of the study treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentages of Participants With Palmoplantar Investigator Global Assessmnet (ppIGA) 0 or 1 Response After 16 Weeks of Treatment","description":"palmoplantar Investigator's Global Assessment (ppIGA) response after 16 weeks of treatment. To be considered a ppIGA responder at Week 16, a subject must have ppIGA of 0 or 1 at Week 16 and a reduction of at least 2 points on the ppIGA scale from baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"33.3","spread":null},{"groupId":"OG002","value":"1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Participants With Palmoplantar Investigator Global Assessment (ppIGA) 0 or 1 Response - Treatment Period I","description":"ppIGA: Palmoplantar Ivestigator's Global Assessment. The IGA mod 2011 rating scale: The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.\n\nBased on this scale, a patient was considered as an IGA 0 or 1 responder if they achieved a score of 0 or 1 and improved by at least 2 points on the IGA scale at a given time point compared to their score at randomization (baseline).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"1.4","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":null},{"groupId":"OG001","value":"7.2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"8.7","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":null},{"groupId":"OG001","value":"26.1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":null},{"groupId":"OG001","value":"33.3","spread":null},{"groupId":"OG002","value":"1.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":null},{"groupId":"OG001","value":"33.3","spread":null},{"groupId":"OG002","value":"1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With ppIGA 0 or 1 Response (Observed Cases) - Treatment Period II","description":"ppIGA: Palmoplantar Ivestigator's Global Assessment. The IGA mod 2011 rating scale: The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.\n\nBased on this scale, a patient was considered as an IGA 0 or 1 responder if they achieved a score of 0 or 1 and improved by at least 2 points on the IGA scale at a given time point compared to their score at randomization (baseline).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":"15.624"},{"groupId":"OG001","value":"33.3","spread":"12.074"},{"groupId":"OG002","value":"0.0","spread":"8.880"},{"groupId":"OG003","value":"0.0","spread":"7.983"},{"groupId":"OG004","value":"100.0","spread":"4.479"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":"14.307"},{"groupId":"OG001","value":"33.3","spread":"13.104"},{"groupId":"OG002","value":"12.9","spread":"11.570"},{"groupId":"OG003","value":"9.7","spread":"12.625"},{"groupId":"OG004","value":"0.0","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":"15.232"},{"groupId":"OG001","value":"44.9","spread":"14.258"},{"groupId":"OG002","value":"32.3","spread":"14.560"},{"groupId":"OG003","value":"51.6","spread":"10.441"},{"groupId":"OG004","value":"100.0","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":"14.658"},{"groupId":"OG001","value":"42.0","spread":"11.688"},{"groupId":"OG002","value":"35.5","spread":"11.728"},{"groupId":"OG003","value":"41.9","spread":"5.844"},{"groupId":"OG004","value":"0.0","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":null},{"groupId":"OG001","value":"46.4","spread":null},{"groupId":"OG002","value":"29.0","spread":null},{"groupId":"OG003","value":"48.4","spread":null},{"groupId":"OG004","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":null},{"groupId":"OG001","value":"27.5","spread":null},{"groupId":"OG002","value":"12.9","spread":null},{"groupId":"OG003","value":"35.5","spread":null},{"groupId":"OG004","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects With ppIGA 0 or 1 Response (Observed Cases) - Entire Treatment Period","description":"ppIGA: Palmoplantar Ivestigator's Global Assessment. The IGA mod 2011 rating scale: The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.\n\nBased on this scale, a patient was considered as an IGA 0 or 1 responder if they achieved a score of 0 or 1 and improved by at least 2 points on the IGA scale at a given time point compared to their score at randomization (baseline).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.4","spread":null},{"groupId":"OG001","value":"37.7","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.7","spread":null},{"groupId":"OG001","value":"44.1","spread":null},{"groupId":"OG002","value":"20.0","spread":null},{"groupId":"OG003","value":"36.7","spread":null},{"groupId":"OG004","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":null},{"groupId":"OG001","value":"50.8","spread":null},{"groupId":"OG002","value":"20.0","spread":null},{"groupId":"OG003","value":"48.3","spread":null},{"groupId":"OG004","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.7","spread":null},{"groupId":"OG001","value":"65.3","spread":null},{"groupId":"OG002","value":"45.0","spread":null},{"groupId":"OG003","value":"68.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline for Palmoplantar Psoriasis Area and Severity Index (ppPASI) Score -Treatment Period I","description":"Psoriasis Area and Severity Index (PASI) is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.13","spread":"4.797"},{"groupId":"OG001","value":"-2.22","spread":"4.334"},{"groupId":"OG002","value":"-0.85","spread":"3.355"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.11","spread":"7.669"},{"groupId":"OG001","value":"-5.32","spread":"6.120"},{"groupId":"OG002","value":"-1.90","spread":"5.434"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.69","spread":"9.890"},{"groupId":"OG001","value":"-9.18","spread":"9.734"},{"groupId":"OG002","value":"-3.95","spread":"7.424"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.74","spread":"12.779"},{"groupId":"OG001","value":"-11.30","spread":"11.954"},{"groupId":"OG002","value":"-3.22","spread":"8.316"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.15","spread":"14.409"},{"groupId":"OG001","value":"-12.83","spread":"12.286"},{"groupId":"OG002","value":"-3.07","spread":"8.479"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.41","spread":"15.984"},{"groupId":"OG001","value":"-13.35","spread":"12.941"},{"groupId":"OG002","value":"-2.43","spread":"8.527"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline for Palmoplantar Psoriasis Area and Severity Index (ppPASI) Score (Observed Cases) - Entire Treatment Set","description":"Psoriasis Area and Severity Index (PASI) is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.97","spread":"15.624"},{"groupId":"OG001","value":"-12.67","spread":"12.074"},{"groupId":"OG002","value":"-1.57","spread":"8.880"},{"groupId":"OG003","value":"-3.11","spread":"7.983"},{"groupId":"OG004","value":"-7.15","spread":"4.479"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.29","spread":"14.307"},{"groupId":"OG001","value":"-17.43","spread":"13.104"},{"groupId":"OG002","value":"-15.49","spread":"11.570"},{"groupId":"OG003","value":"-15.09","spread":"12.625"},{"groupId":"OG004","value":"-11.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.05","spread":"15.232"},{"groupId":"OG001","value":"-19.27","spread":"14.258"},{"groupId":"OG002","value":"-13.71","spread":"14.560"},{"groupId":"OG003","value":"-16.70","spread":"10.441"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.74","spread":"14.658"},{"groupId":"OG001","value":"-19.16","spread":"11.688"},{"groupId":"OG002","value":"-17.07","spread":"11.728"},{"groupId":"OG003","value":"-13.82","spread":"5.844"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Developing Anti-secukinumab Antibodies","description":"To investigate the development of immunogenicity against secukinumab","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19,"n":99},"commonTop":["Upper respiratory tract infection","Psoriasis","Nasopharyngitis","Headache","Influenza"]}}}